Sarepta therapeutics completes enrollment in emergene, a phase 3 clinical study of srp-9003 for the treatment of limb-girdle muscular dystrophy type 2e/r4

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in emergene (study srp-9003-301), a phase 3 clinical trial of srp-9003 (bidridistrogene xeboparvovec). srp-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy type 2e/r4 (lgmd2e/r4), or beta-sarcoglycanopathy. emergene is a global study, and the primary endpoint is t.
SRPT Ratings Summary
SRPT Quant Ranking